Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report) shares fell 6.7% on Friday . The stock traded as low as $16.22 and last traded at $16.30. 9,267 shares were traded during trading, a decline of 64% from the average session volume of 25,931 shares. The stock had previously closed at $17.46.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on TLX shares. Wedbush reissued an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Thursday. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a report on Wednesday, March 12th.
Get Our Latest Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Down 7.8%
The business's fifty day moving average price is $16.97 and its 200 day moving average price is $16.92.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Telix Pharmaceuticals Limited American Depositary Shares stock. Private Advisor Group LLC acquired a new stake in Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,140 shares of the company's stock, valued at approximately $170,000.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Recommended Stories
Before you consider Telix Pharmaceuticals Limited American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals Limited American Depositary Shares wasn't on the list.
While Telix Pharmaceuticals Limited American Depositary Shares currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
